---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-25-000038"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2025-01-24T23:59:59+00:00"
generated_at: "2026-05-27T11:00:32.914960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics discloses ~$412M cash balance, awards $540K bonuses to CEO/CFO

## Summary
- Preliminary unaudited cash, equivalents, and short-term investments ~$412M as of Dec 31, 2024, including $31.8M loan repayment.
- CEO Dr. Zanganeh and CFO Manmeet Soni each granted $540K cash bonus for FY2024, payable Q1 2025; no bonus in FY2023.
- Base salaries for both officers increase from $600K to $618K, effective February 1, 2025.
- Cash balance is preliminary and subject to year-end closing adjustments.

## SEC filing metadata
- accession: 0001599298-25-000038
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2025-01-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000038/0001599298-25-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000038/smmt-20250122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-25-000038
- JSON: https://secwatch.observer/filing/0001599298-25-000038.json
- Plain text: https://secwatch.observer/filing/0001599298-25-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.